Skip to main content
Premium Trial:

Request an Annual Quote

Reprocell Acquires BioServe, Reinnervate

NEW YORK (GenomeWeb) – Japanese stem cell products company Reprocell said today that it has purchased 3D cell culture firm Reinnervate and US genomics services firm BioServe.

Sedgefield, UK-based Reinnervate makes the Alvetex line of 3D cell culture products, which will be combined with Reprocell's induced pluripotent stem cells to produce next-generation tools for drug toxicity, neuroscience, and cancer research.

Beltsville, Md.-based BioServe operates a commercial biorepository, which supplies human tissues, serum, and DNA and RNA samples to researchers around the globe. It also provides a variety of genomic services including genotyping, DNA and RNA extraction, gene expression and allelic discrimination using real-time PCR, and molecular diagnostic testing out of its CLIA-certified facility.

Reprocell intends to use its access to the samples in BioServe's respository to generate a wide range of disease-related iPSC lines for use in human cell models.

Financial terms of the acquisitions were not disclosed.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.